We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 165

PTAB Denies Another IPR Petition Relating to Adalimumab
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • June 14 2018

The Patent Trial and Appeal Board (“PTAB”) recently denied Sandoz’s petition for inter partes review (“IPR”) of claims 1-30 of AbbVie’s patent, U.S


Non-Patent Literature at the PTAB
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • June 12 2018

Typically, the Patent Trial and Appeals Board (PTAB) is thought to disfavor non-patent literaturethat is, “printed publications” under 35 U.S.C


Data privacy and cyber security: the importance of a proactive approach
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • June 12 2018

New laws are taking effect across the globe to regulate the collection, use, retention, disclosure and disposal of personal information. At the same


Ignore PTAB Precedent At Your Peril
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • May 30 2018

Given the popularity of AIA post-grant proceedings, many patent litigators have been newly drawn into proceedings before the Patent Trial and Appeal


Litigation Spotlight: The Adello Filgrastim (Neupogen) Litigation
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • May 29 2018

On March 8, 2018, Amgen Inc. (“Amgen”) filed suit against Adello Biologics, LLC (“Adello”) in the District of New Jersey, alleging infringement of


Lilly Announces Positive Results for Galcanezumab in Treating Episodic Cluster Headaches
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • May 25 2018

Last week, Eli Lilly and Company (“Lilly”) announced that galcanezumab met its primary endpoint in a Phase 3 study of patients with episodic cluster


Patent-Ineligibility of Mathematical Techniques in SAP America: Is there a distinction to be made between finance and artificial intelligence innovations backed by mathematics?
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • May 23 2018

No matter how groundbreaking, innovative, or brilliant the advance, innovators in mathematical techniques, particularly in the finance field, may


Novartis and Amgen Announce FDA Approval of Aimovig
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • May 23 2018

Last week, Novartis and Amgen announced the FDA approved Aimovig (erenumab) for the preventive treatment of migraine in adults. The FDA granted


Litigation Spotlight Update: Epogen Litigation Status in Face of Retacrit Regulatory Approval
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • May 22 2018

As we recently covered, May 15, 2018, saw the FDA granting approval to Hospira (now a Pfizer subsidiary) for its Retacrit injection, a biosimilar to


Celltrion Seeks Joinder with Pfizer IPR Challenging Rituximab-Related Patent
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • May 18 2018

Earlier this month, Celltrion, Inc. (“Celltrion”) filed a copycat IPR petition directed against U.S. Patent No. 7,976,838 (“the ʼ838 patent”) that is